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CHAPTER 1: Introduction
Skin cancer is the most common form of cancer in the world.1,2,3 It is generally split
between two main categories: melanoma from melanocytes, and non-melanoma skin cancer
(NMSC), which consists of basal cell and squamous cell carcinomas. Melanoma is the least
common, but the most malignant. Basal cell carcinoma (BCC) is the most benign and also the
most prevalent. It accounts for 80% of all skin cancers, making it the most common form of any
cancer in the world.1 BCC presents as a “flat, firm, pale areas” or “small, raised, pink or red bumps
that may bleed after a minor injury.”1,2 Treatment often involves surgical removal of the affected
area and can leave disfiguring scars, especially in cases of large tumors.1 Additionally, scarring
from tumors located in regions around the eyes, ears, and mouth may be structurally
compromising and aesthetically displeasing.4 Instances of BCC are increasing, and because of its
prevalence and recurrence, the cost to healthcare is tremendous. Over the last decade or so the
cost of treating skin cancer has jumped from $3.6 billion to $8.1 billion annually, an increase of
126.6%. Of that, NMSC accounted for an increase from $2.7 to $4.8 billion.3 For these reasons,
non-invasive outpatient treatments for basal cell carcinoma are of great interest.4
Vitamin D3 supplementation is often considered in the treatment of cancer, including BCC,
due to its well-documented anti-proliferative effects.5,6 In the absence of vitamin D signaling,
mice exposed to ultraviolet (UV) light develop skin cancer, underscoring its importance.7,8
Indeed, the regulatory role of vitamin D most likely evolved from a necessity to protect against
the harmful effects of UV light.6

However, while adequate levels may be protective,

supplementation may not necessarily add additional benefit. Animal and cell culture studies
have in fact found protective effects of vitamin D in several forms of cancer models, and clinical
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studies of supplementation have been positive in cases of breast and colorectal cancer.8,9
Unfortunately, human clinical studies of BCC have been rare and inconclusive as to its actual
benefit, and intervention studies are essentially non-existent. Analysis of two prospective cohort
studies found no association between dietary vitamin D intake and BCC occurrence in men or
women.10,11 Another study found an inverse relationship between serum levels of the circulating
form of vitamin D and NMSC in elderly men.12 On the other hand, studies have also shown that
high serum levels actually increase the risk of developing BCC.13,14 The data is further confounded
because of the varied impact of vitamin D3 on multiple signaling pathways and the mutagenic
nature of the cancer. More data is needed to elucidate the actual effects of vitamin D treatment
in BCC.
Vitamin D is a general term for a group of fat soluble vitamins that are most notably
responsible for calcium homeostasis in the body.15 The most common forms are vitamin D2
(ergocalciferol) and D3 (cholecalciferol), and it is D3 that shows promise in the treatment of
cancer. The metabolism of vitamin D3 involves several steps that occur in different organs (Figure
1.1). The body is capable of synthesizing 7-dehydrocholesterol in the skin, however, this form of
the vitamin requires UV light to convert it to cholecalciferol. Cholecalciferol can also be provided
in the diet by a limited number of foods, such as eggs and fortified milk.6,16 It is this form that is
referred to as vitamin D3, although it still requires the addition of two hydroxyl groups before it
is biologically active. Cholecalciferol first must travel to the liver, where the enzyme vitamin D
25-hydroxylase (25-OHase) converts it to 25-hydroxycholecalciferol, also known as calcidiol.
Next, the vitamin precursor travels to the kidneys, where the enzyme 25-hydroxyvitamin D3 1alpha-hydroxylase (1α-OHase) converts it to 1,25-dihydroxycholecalciferol, or calcitriol.6,16 This
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is the active form, which is capable of binding the vitamin D receptor (VDR), a transcription factor
that controls the expression of over 900 genes, many of which are involved in cell cycle
regulation, differentiation, and apoptosis.17 Therefore, vitamin D3 and its receptor may play an
important role in the treatment of cancer, possibly by way of controlling cellular proliferation.
One theory behind vitamin D3 supplementation in cases of BCC is that by providing
additional vitamin D3 one can prevent uncontrolled cell growth by encouraging VDR-induced
inhibition of cellular proliferation.

Also present in the kidneys is an enzyme called 25-

hydroxyvitamin D3-24-hydroxylase (24-OHase), which adds a third hydroxyl group to vitamin D3.
This enzyme is up-regulated in response to calcitriol, and results in its inactivation and
degradation to calcitroic acid.6,16 High expression of 24-hydroxylase was associated with poor
survival in lung cancer patients.17 Interestingly, all three of these enzymes are also expressed in
the skin, demonstrating the importance of a reliable balance of vitamin D3 in this organ, perhaps
as an immediate defense mechanism against the harmful effects of UV radiation.18

Figure 1.1 Vitamin D3 metabolism

One of the signaling cascades that VDR regulates is the mTOR pathway (Figure 1.2). The
mammalian target of rapaycin (mTOR) is a major control switch involved in cell survival, growth,
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and proliferation. mTOR phosphorylates its targets, S6K and 4EBP, which results in the activation
of protein synthesis.19 This pathway is often up-regulated in cancer, whereas down-regulation is
associated with differentiation and apoptosis. Therefore, compounds that can negatively
regulate the mTOR pathway have the potential to be powerful anti-cancer drugs. When calcitriol
binds to VDR, one of the genes that is up-regulated is DNA-damage-inducible transcript 4 (DDIT4),
also known as regulated in development and DNA damage response 1 (REDD1).19 REDD1
activates TSC1 and TSC2. These proteins are responsible for inhibiting Rheb, which in turn is an
activator of mTOR. By up-regulating REDD1 via VDR, vitamin D3 is thought to inhibit mTOR and
thus its ability to phosphorylate S6K and 4EBP.19 In fact, Lisse et al. saw a 50% reduction in cellular
proliferation of osteoblasts in response to calcitriol treatment.20 They determined this to be an
effect of the demonstrated increase in REDD1 protein, resulting in a decrease in phosphorylation
of S6K.

Figure 1.2 Vitamin D3 and the mTOR pathway

The described vitamin D – mTOR pathway is just a small segment of a much larger signal
transduction picture. This pathway shares downstream targets of the RAS-RAF-MEK-ERK and
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PI3K/AKT pathways (Figure 1.3).21 Ras is a GTPase that is active when bound to GTP, and inactive
when bound to GDP. When activated, Ras induces translocation and phosphorylation of RAF,
resulting in its activation. Activated RAF then phosphorylates MEK, which phosphorylates
extracellular signal-regulated kinases 1 and 2 (ERK1/2). ERK1/2 can then activate mTOR. Ras is
also capable of activating phosphinositide-3 kinase (PI3K).

PI3K phosphorylates

phosphatidylinositol bisphosphate (PIP2), forming PIP3, which activates protein kinase B (AKT).
AKT is a kinase that is responsible for phosphorylating several proteins, including TSC 2. This
phosphorylation inhibits TSC1 and TSC2, preventing them from down-regulating Rheb, which can
potentially lead to the activation of mTOR. Therefore, Ras can indirectly activate mTOR through
both of these pathways, contributing to increased cell growth and proliferation.

Figure 1.3 RAS activation of mTOR via RAF/MEK/ERK (a) and PI3K/AKT (b)

Indeed, both pathways were shown to be involved synergistically in the development of
esophageal cancer. Wei and Xu showed that phosphorylation of both AKT and ERK was increased
in cancer patients.22 Interestingly, in many cancers, and as observed in our laboratory in human
BCC tissue, a gain of function mutation is often seen in Ras.23 Our lab also reported an increase
in expression of Ras mRNA in cancer tissue. Over-activity of Ras signaling pathways may
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overwhelm any inhibition from vitamin D3 supplementation via VDR/REDD1/mTOR signaling. To
make matters worse, oncogenic Ras may also reduce the expression of VDR. Rozenchran et al.
found that over-expression of Ras led to reduced levels of VDR due to mRNA instability.24
Considering all of these factors collectively may help explain why the effectiveness of vitamin D3
treatment is so inconsistent in clinical studies.
Another pathway involved in BCC progression is the Hedgehog (HH) pathway (Figure 1.4).
Patched1 (PTCH1) is a membrane receptor that binds to and inhibits Smoothened (SMO). Sonic
hedgehog protein (HH) disrupts this inhibition, allowing SMO to activate Gli proteins. These
proteins are transcription factors that then up-regulate genes involved in cellular proliferation.
Mutations in this pathway, such as those that destroy the ability of PTCH1 to inhibit SMO, are the
most common found in basal cell carcinoma.25

Figure 1.4 The Hedgehog pathway

In a second mechanism of the anti-cancer effects of vitamin D3, Uhmann et al. showed
that calcitriol inhibits the HH pathway in a VDR-independent fashion by inhibiting SMO directly.26
Tang, et al. disagree with this finding, on the basis of the form of vitamin D3 that is responsible
for the inhibition of SMO.

They showed that only the non-hydroxylated vitamin D3,
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cholecalciferol, could inhibit cellular proliferation.27 They also showed that cholecalciferol could
reduce Gli1 mRNA, but the hydroxylated forms could not.
In contrast to the studies by Uhmann and Tang, Teichert et al. found that calcitriol is
involved in the VDR-dependent gene down-regulation of several of the hedgehog signaling
pathway proteins.8 They also demonstrated that in the absence of VDR several of these genes
were over-expressed. Despite their disagreement on the mechanism involved, these studies
make a strong argument for the inclusion of vitamin D3 in the treatment of basal cell carcinoma.
Complicating the picture further, Wang et al. showed that activation of the mTOR
pathway is capable of activating Gli proteins.27 This activation was shown to come from S6K and
occurred in the absence of SMO, signifying the complex inter-relationship of the hedgehog and
RAS/PI3K pathways. This data was supported by another study in which a RAS/RAF pathway
inhibitor was able to decrease Gli1 mRNA and protein expression.28 Furthermore, in a study
published in 2013, researchers demonstrated that mice with RAS mutations required Gli for the
formation of pancreatic cancer.29 They also found that RAS up-regulated the expression of HH,
thus resulting in the activation of Gli.
Mutations resulting in dysfunction of the HH pathway are the most common in BCC.
However, as mentioned, they are often not the only mutations present. Up-regulation of RAS or
other oncogenes may negate the protective effect of vitamin D3 by overwhelming it and/or
circumventing it. This complex relationship stresses the importance of dual-pathway inhibitors
in the treatment of cancer. A compound that is capable of down-regulating aspects of both
pathways could have tremendous benefit in the treatment of this form of cancer.
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Despite its promise in vitro, vitamin D3 has yet to be proven effective in the clinical
treatment of basal cell carcinoma. In a personal communication between clinical practitioners
and our laboratory, the need for more research into the molecular mechanisms involved in this
treatment was discussed. If supplementation is not beneficial perhaps it should no longer be
prescribed. Previous work in our laboratory involved comparison of gene expression in cancer,
proximal, and distal tissue taken from the head and neck regions of human patients. Our
research indicated that genes involved in both the metabolism and signaling of vitamin D3 were
up-regulated in cancer tissue. Whether this is an innate defense against cancer, an effect of the
cancer itself, or a combination of the two is yet to be determined.

Specific Aim
In addition to its role in bone mineralization and calcium homeostasis, Vitamin D3 has
been implicated as a major regulator of cellular proliferation and differentiation. The antiproliferative impact of Vitamin D3 is observed in clinical studies of breast and colon cancer, where
vitamin D3 treatment is generally positive. However, clinical data on vitamin D3 treatment of
basal cell carcinoma (BCC) is lacking and inconclusive at best. Because the majority of the in vitro
studies in support of the protective effects of vitamin D3 in onset and progression of cancer were
not performed in skin cells these findings may not be applicable to BCC. Unfortunately, the nonmetastatic nature of BCC makes cell lines difficult to grow in culture.30 The goal of this study is
to determine the impact of vitamin D3 on proliferation of an immortalized human keratinocyte
cell (HaCaT), a model for the basal layer of the skin. The HaCaT cells were spontaneously
immortalized in vitro without transformation. Their name references their Human Adult origin,
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and their immortalization treatment of low Calcium and high Temperature. The HaCaT cells
exhibit normal differentiation markers and are non-tumorigenic.31
Previous data in our laboratory indicate that the Hedgehog and mTOR-signaling pathways
are activated in BCC tissue, despite increased expression of active vitamin D3.23 Therefore, I
hypothesize that vitamin D3 treatment will increase proliferation of HaCaT cells by modulating
the mTOR-signaling pathway and failing to inhibit the Hedgehog pathway. Thus, vitamin D3
treatment of skin cancer is ineffective and potentially detrimental. This hypothesis will be tested
by the following specific aims:
1. To determine the impact of calcitriol and cholecalciferol on proliferation of HaCaT
cells
2. To dissect the molecular mechanism by which vitamin D3 supplementation alters the
proliferation of HaCaT cells.
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CHAPTER 2: Materials and Methods
Cell Culture
Human keratinocyte (HaCaT) cells were obtained from AddexBio. Cultures were grown in
Gibco DMEM High Glucose media supplemented with 10% FBS and antibiotics. Cells were
subcultured approximately twice weekly. Media was purchased from Life Technologies.

Treatment
Calcitriol was purchased from Sigma Aldrich. A 10-5 M stock solution was prepared in
ethanol. Cholecalciferol was purchased from Fisher Scientific. A 1 M stock solution was prepared
in ethanol. Ten-fold serial dilutions were made from each stock. Treatments were prepared 1%
v/v in complete media. Concentrations tested were 10-8 M and 10-7 M calcitriol, and 5x10-6 M
and 10-5 M cholecalciferol, as found in the literature.12
5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) was purchased from
Toronto Research Chemicals. This molecule phosphorylates AMPK, mimicking low energy status
([ATP]/[AMP]), which then results in inhibition of proliferation.32 It will be used as a positive
control, as vitamin D3 inhibits proliferation independently of AMPK. A 1 M stock solution was
prepared in DMSO. Ten-fold serial dilutions were made. Treatments were prepared 1% v/v in
complete media. Concentrations tested were 10-4 M and 10-3 M, as found in the literature.32
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WST-1 Cell Proliferation Assay
WST-1 cell proliferation reagent was purchased from Roche. Viable, proliferating cells
express active mitochondrial dehydrogenases. This assay exploits the activity of these enzymes
to compare proliferation of cells following different treatment conditions. The enzymes cleave
tetrazolium salts in the WST-1 reagent to produce formazan, a dye that absorbs at 420-480 nm.
The absorbance directly correlates to the number of viable cells in the sample.
Cells were plated in 96-well tissue culture-treated plates at a concentration of 4000 cells
per well and allowed to recover overnight. The next day, media was replaced with the treatments
listed in Table 2.1. After 24 or 48 hours, treatment media was replaced with complete media
containing 10% WST-1 reagent. Three wells were reserved for blanks, in which no cells had been
plated. Following four hours of incubation at 37°C the absorbance was read at 450 nm. Average
blank absorbance was subtracted from all samples. Changes in proliferation following vitamin or
AICAR treatment were compared to controls treated with vehicle alone. Results are given as
fold-change versus controls, with controls normalized to 1.

Table 2.1 Treatment of HaCaT keratinocyte cells for MTT cell proliferation assay.
EtOH Vehicle
10 nM Calcitriol
100 nM Calcitriol
5 µM Cholecalciferol
10 µM Cholecalciferol
DMSO Vehicle
0.1 mM AICAR
1 mM AICAR

1 µL EtOH
1µL 1 µM Stock
1 µL 10 µM Stock
1 µL 500 µM Stock
1 µL 1 mM Stock
1 µL DMSO
1 µL 10 mM Stock
1 µL 100 mM Stock

100 µL Media
100 µL Media
100 µL Media
100 µL Media
100 µL Media
100 µL Media
100 µL Media
100 µL Media
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RNA Isolation and cDNA Synthesis
Cells were plated in 6-well tissue culture-treated plates at a concentration of 5x104 cells
per well and allowed to recover overnight. The next day, media was replaced with the treatments
listed in Table 2.2. After 24 or 48 hours of treatment, cells were rinsed with PBS, and RNA was
extracted using the TRIzol method (Life Technologies). RNA concentrations were measured with
the Nanodrop UV/Vis spectrophotometer. Next, 1 µg of RNA was used to synthesize cDNA using
the Promega ImProm-II™ Reverse Transcription System. RNA was first incubated with random
primers in a volume of 10 µL at 70°C for five minutes. Next, master mix was added to each tube,
which contained 4 µL 5x buffer, 4 µL MgCl2, 1 µL dNTPs, and 1 µL reverse transcriptase. Samples
were placed in an Eppendorf thermocycler.

The reverse transcription (RT-PCR) program

consisted of the following steps: 25°C for five minutes, 42°C for one hour, 70°C for 15 minutes,
and a 4°C hold. The reaction products were then purified with the Qiagen QIAquick® PCR
Purification Kit. From the four samples from each treatment group, the three with the highest
concentrations were chosen to use for RealTime PCR.

Table 2.2 Treatment of HaCaT keratinocyte cells for RNA isolation
EtOH Vehicle
100 nM Calcitriol
10 µM Cholecalciferol

20 µL EtOH
20 µL 10 µM Stock
20 µL 1 mM Stock

2 mL Media
2 mL Media
2 mL Media

Real-Time PCR
Primers were purchased from Sigma Aldrich and reconstituted as 100 µM Stocks.
Working stocks consisted of 5 µM forward plus 5 µM reverse primer. Primer sequences are listed
in Table 2.3. The LightCycler® 480 SYBR Green I Master kit from Roche was used to prepare
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samples for qPCR. Samples consisted of 12.5 µL MasterMix from the kit, 1 µL primer mix (0.75
µL for 25OHase), 3 µL cDNA (30.3 ng for 24 hour samples, 41.55 ng for 48 hour samples) and
DNAse-free water to 23 µL. Reactions were performed in a Stratagene thermocycler, and
consisted of a five minute 95°C pre-incubation step, followed fifty cycles of amplification (ten
seconds at 95°C followed by 30-60 seconds at the annealing temperature listed in Table 2.3) after
which SYBR Green fluorescence was measured. A third segment generated dissociation curve
data, and consisted of heating the samples to 95°C for one minute, cooling to the proper
annealing temperature for 30-60 seconds, and then heating to 95°C again, while constantly
measuring fluorescence. Threshold cycle (Ct) values were collected. First, data was compared
to the average of the controls (ΔCt) and then calculated as fold-change versus controls (2-ΔCt).
Data is presented with controls normalized to 1.

Table 2.3 Real-Time PCR Primer Sequences and Annealing Temperatures
Target
VDR fwd
VDR rev
25OHase fwd
25OHase rev
1αOHase fwd
1αOHase rev
24OHase fwd
24OHase rev
Gli1 fwd
Gli1 rev
REDD1 fwd
REDD1 rev
KRAS fwd
KRAS rev

Sequence
CCAGTTCGTGTGAATGATGG
GTCGTCCATGGTGAAGGA
GGCAAGTACCCAGTACGG
AGCAAATAGCTTCCAAGG
TGTTTGCATTTGCTCAGA
CCGGGAGAGCTCATACAG
GCAGCCTAGTGCAGATTT
ATTCACCCAGAACTGTTG
CTCCCGAAGGACAGGTATGTAAC
CCCTACTCTTTAGGCACTAGAGTTG
GGTCACTGAGCAGCTCGAA
CCTGGACAGCAGCAACAGT
AAACTTGTGGTAGTTGGAGCTGG
TGATTCTGAATTAGCTGTATCGTCAA

Tm
64.1
62.3
60.6
57.0
59.0
61.0
58.1
55.7
64.5
62.3
64.6
64.3
55.3
53.2

Annealing Temp
57.0
57.0
55.0
55.0
59.0
59.0
55.0
55.0
57.0
57.0
63.0
63.0
50.0
50.0
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Protein Isolation and Quantification
Cells were plated in 100 mm tissue culture-treated dishes at a concentration of 5x105 cells
per dish and allowed to recover overnight. The next day, media was replaced with the treatments
listed in Table 2.4. After 24 or 48 hours of treatment, plates were rinsed with PBS, and cells were
incubated in 700 µL lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 1 mM
EDTA, 1 mM EGTA, 1 mM PMSF, 0.1% SDS, 0.5% sodium deoxycholate, 1x protease inhibitor) for
30 minutes at 4°C. Following incubation, cells were collected with a cell scraper and placed at 80°C overnight.

Following freeze-thaw, lysates were spun to remove pellet and then

concentrated to <100 µL in 10 kDa spin column concentration units. Concentrations were
determined using the Pierce BCA Assay Kit. Samples were prepared in Laemmli buffer and heated
to 70°C for 5 min before running SDS PAGE.

Table 2.4 Treatment of HaCaT keratinocyte cells for protein isolation.
EtOH Vehicle
100 nM Calcitriol
10 µM Cholecalciferol
DMSO Vehicle
1 mM AICAR

100 µL EtOH
100 µL 10 µM Stock
100 µL 1 mM Stock
100 µL DMSO
100 µL 100 mM Stock

10 mL Media
10 mL Media
10 mL Media
10 mL Media
10 mL Media

SDS PAGE and Western Blot
50 µg of whole cell extract samples were separated by SDS polyacrylamide gel
electrophoreses (PAGE) using 4-15% or 10% Criterion™ TGX Stain-Free™ Precast gels (Bio-Rad).
These gels were run at 250 V until the dye front reached the bottom of the gel (approximately
thirty minutes). They were then activated in the Bio-Rad Gel Doc™ EZ Imager, using the Image
Lab™ software prior to being transferred onto nitrocellulose membrane at 75 V for 15 minutes.
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The activation step involves the UV linkage of trihalo compounds in the precast gels to tryptophan
residues in the proteins. This produces fluorescence that can be detected by the imaging
software. The membranes were then imaged post-transfer to observe transfer efficiency. After
transfer membranes were blocked in 5% milk for 45-60 minutes. Membranes were then
incubated overnight in primary antibody solutions of TBS-Tween containing 5% BSA and sodium
azide (Table 2.5). HRP-conjugated secondary antibody solutions were prepared in TBS-Tween
containing 5% BSA. Blots were first probed with phospho-antibodies, followed by a stripping step
(Restore™ Thermo Scientific) before probing with their total protein-specific antibody
counterparts. Blots were incubated with SuperSignal® West Pico or Femto chemiluminescent
substrate (Thermo Scientific) before detection in the gel imager using the Quantity One® 1-D
Analysis software. Bands were detected and quantified with the Image Lab™ software. The
change in phosphorylation of three proteins of interest was calculated. Results are given as foldchange versus controls, with controls normalized to 1.

Table 2.5 Antibodies used in Western Blot
Target
phospho-4EBP, Thr 37/46
Total 4EBP
phospho-p70-S6K, Thr 389
Total p70-S6K
phospho-mTOR, Ser 2448
Total mTOR
Anti-rabbit
Anti-mouse

Vendor
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Santa Cruz
Santa Cruz

Catalog #
236B4
9644
9206
2708
5536
2983
Sc-2301
Sc-2302

Dilution
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1-10,000
1:10,000

Species
Rabbit
Rabbit
Mouse
Rabbit
Rabbit
Rabbit
Goat
Goat

Statistical Analysis
A t test was performed to analyze all data. A p value of less than 0.05 was considered significant.
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CHAPTER 3: Results
WST-1 CELL PROLIFERATION ASSAY
HaCaT cells were treated for 24 or 48 hours with two forms of vitamin D3, calcitriol and
cholecalciferol. Results presented are from three independent experiments. Following 24 hours
of treatment 100 nM calcitriol increased cellular proliferation significantly (p = 0.03). The
absorbance at 450 nm increased by 19%, which directly correlates to a 19% increase in viable
cells. The other three treatment groups at this time point were not significantly different from
controls (Figure 3.1). Following 48 hours of treatment, all four groups had a significant increase
in proliferation versus controls (p < 10-5). 10 nM and 100 nM Calcitriol increased proliferation by
23% and 25%, respectively. 5 µM and 10 µM cholecalciferol increased proliferation by 29% and
32%, respectively (Figure 3.2).
HaCaT cells were treated for 24 or 48 hours with AICAR. Results presented are from three
independent experiments. Following 24 hours of treatment 1 mM AICAR decreased cellular
proliferation significantly by 32% (p < 10-5) (Figure 3.3). After 48 hours of treatment, both
treatment groups had a significant decrease in proliferation versus controls; 0.1 mM AICAR
decreased proliferation by 14% (p = 0.004), and 1 mM AICAR decreased proliferation by 42% (p
< 10-10) (Figure 3.4).

REAL-TIME PCR
HaCaT cells were treated in with 100 nM calcitriol, 10 µM cholecalciferol, or EtOH vehicle
for 24 or 48 hours. Isolated RNA was used to create cDNA, which was then used to perform Realtime analysis of several genes of interest. Dissociation curves were analyzed for all genes to
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exclude amplification results attributed to the presence of primer dimers. The 25OHase reaction
was repeated with 25% less primer to remove primer dimer amplification. Genes tested were
the vitamin D3 metabolizing genes (25OHase, 1αOHase, and 24OHase), three genes hypothesized
to be affected by vitamin D3 treatment (VDR, REDD1, and Gli1), and Ras. Ras was chosen because
previous data from our laboratory showed an increased in Ras expression alongside increases in
vitamin D activating enzymes in BCC tissue. We wanted to determine whether or not this was
directly caused by an increase in active vitamin D. The samples called 24h Calcitriol-3 and 48h
Calcitriol-2 both appear to be outliers, and each increases the average CT values for their groups.
They have not been excluded, but will be addressed for each gene when necessary.

25-OHase) Calcitriol treatment did not have an effect on expression of this gene following 24
hours of treatment. On average, the 48 hour treatment samples did not have an effect on this
gene. One sample, Calcitriol-3, had a two-fold increase, which brought the average close to that
of controls. When this sample is excluded the group has a reduction in 25OHase expression,
although the data is not significant (p = 0.1). Cholecalciferol appeared to increase expression
following 24 hours, however the data is not significant. Following 48 hours of treatment with
cholecalciferol, 25OHase cDNA is significantly decreased compared to controls (p = 0.01) (Figure
3.5).

1α-OHase) Calcitriol treatment did not have an effect on expression of this gene. Removal of
both the 24 and 48 hour outliers brought the averages of these groups closer to that of controls.
Cholecalciferol did not have an effect on expression following 24 hours. However, following 48
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hours of treatment with cholecalciferol, 1αOHase cDNA was significantly elevated above controls
(p = 0.04) (Figure 3.6).

24-OHase) Both calcitriol and cholecalciferol treatment increased the expression of this gene.
The 24 hour data is not significant due to the variation within the groups, even when the outlier
is excluded. However, the trend is clearly evident and is supported by the several thousand-fold
scale of the y-axis. Following 48 hours of treatment the increase in expression with calcitriol and
cholecalciferol treatment is significant (p < 0.015 and 10-5, respectively). Excluding the outliers
in the calcitriol treatment groups does not eliminate the significance (Figure 3.7).

VDR) Calcitriol treatment did not have an effect on this gene. Average fold-change was similar
to controls, and exclusion of outliers brought the data even closer to controls. Cholecalciferol
treatment significantly increased VDR gene expression (p = 0.04). This increase was gone after
48 hours (Figure 3.8).

REDD1) 24 hour treatment with calcitriol did not affect the expression of this gene, especially
when the outlier was removed. 48 hour treatment indicated a trend of increased expression (p
= 0.08), however the variation within the data prevented it from being significant, even with
exclusion of the outlier. Cholecalciferol treatment had a trend of increasing expression at 24
hours. This increase was significant following 48 hours of treatment (p = 0.01) (Figure 3.9).
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Gli1) Neither calcitriol nor cholecalciferol treatment had an effect on the expression of this gene
following 24 or 48 hours of treatment (Figure 3.10).

RAS) Neither calcitriol nor cholecalciferol treatment had an effect on the expression of this gene
following 24 or 48 hours of treatment (Figure 3.11).

WESTERN BLOT
HaCaT cells were treated with Calcitriol, Cholecalciferol, or AICAR for 24 or 48 hours.
Whole cell extract was isolated and analyzed by western blot. Membranes were probed with
antibodies for phosphorylated mTOR and total mTOR; phosphorylated S6K and total S6K; and
phosphorylated 4EBP and total 4EB.

mTOR) Both calcitriol and cholecalciferol 24 hour treatment resulted in a significant increase in
phosphorylated mTOR (p = 0.04 and 0.02, respectively). Calcitriol increased levels by 2.8 fold,
while cholecalciferol increased levels by 2.3-fold. Phosphorylation of mTOR returned to control
levels after 48 hours (Figure 3.12).

P70-S6K) Both calcitriol and cholecalciferol treatment appeared to increase phosphorylation of
S6K following 24 hours of treatment, however the data was not significant (p = 0.14 and 0.17,
respectively). The trend is gone following 48 hours of treatment (Figure 3.13). Data are a
combination of two western blots with the same samples.
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4EBP) Neither calcitriol nor cholecalciferol treatment significantly increased phosphorylation of
4EBP following 24 hour treatment, however, a trend is evident. After 48 hours of treatment,
both forms of the vitamin significantly increased 4EBP phosphorylation status (p = 0.0008 and
0.005, respectively) (Figure 3.14).

Calcitriol treatment resulted in a two-fold increase in

phosphorylated 4EBP, while cholecalcitriol increased the levels by 2.5-fold.

Data are a

combination of two western blots with the same samples.

AICAR Treatment) As a control, cells were treated with 1 mM AICAR for 48 hour and whole cell
extract was analyzed via western blot. The same proteins were probed for as the vitamin D3
treatment blots. Treatment with AICAR resulted in a significant decrease in phosphorylation of
all three proteins tested (pmTOR = 0.03, pS6K = 0.02, p4EBP = 0.04) (Figure 3.15). The decrease is
phosphorylation of mTOR was by 91%.

Phosphorylation of P70-S6K decreased by 55%.

Phosphorylation of 4EBP decreased by 45%. The data for 4EBP were a combination of two
western blots with the same samples.
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Figure 3.1. Cellular proliferation following 24 hour treatment with vitamin D3. HaCaT cells were
treated for 24 hours with calcitriol (10 nM and 100 nM), cholecalciferol (5 µM and 10 µM), or
vehicle. Cells were then incubated with WST-1 reagent for four hours at 37°C. Absorbance was
read at 450 nM. Results are presented as percentage versus controls. A p-value of less than 0.05
is considered significant. Bars with different symbols are significantly different from each other.
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Figure 3.2. Cellular proliferation following 48 hour treatment with vitamin D3. HaCaT cells were
treated for 48 hours with calcitriol (10 nM and 100 nM), cholecalciferol (5 µM and 10 µM), or
vehicle. Cells were then incubated with WST-1 reagent for four hours at 37°C. Absorbance was
read at 450 nM. Results are presented as percentage versus controls. A p-value of less than 0.05
is considered significant. Bars with different symbols are significantly different from each other.
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Figure 3.3. Cellular proliferation following 24 hour treatment with AICAR. HaCaT cells were
treated for 24 hours with AICAR (0.1 mM and 1 mM) or vehicle. Cells were then incubated with
WST-1 reagent for four hours at 37°C. Absorbance was read at 450 nM. Results are presented
as percentage versus controls. A p-value of less than 0.05 is considered significant. Bars with
different symbols are significantly different from each other.
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Figure 3.4. Cellular proliferation following 48 hour treatment with AICAR. HaCaT cells were
treated for 48 hours with AICAR (0.1 mM and 1 mM) or vehicle. Cells were then incubated with
WST-1 reagent for four hours at 37°C. Absorbance was read at 450 nM. Results are presented
as percentage versus controls. A p-value of less than 0.05 is considered significant. Bars with
different symbols are significantly different from each other.
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Figure 3.5. 25-OHase transcript fold change following treatment with vitamin D3. HaCaT cells
were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48
hours (c,d). Real-time PCR was performed using primers specific for 25-hydroxylase. Changes
in expression of this gene are presented as fold change relative to controls. A p-value of less
than 0.05 is considered significant. Bars with different symbols are significantly different from
each other.
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Figure 3.6. 1α-OHase transcript fold change following treatment with vitamin D3. HaCaT cells
were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48
hours (c,d). Real-time PCR was performed using primers specific for 1α-hydroxylase. Changes in
expression of this gene are presented as fold change relative to controls. A p-value of less than
0.05 is considered significant. Bars with different symbols are significantly different from each
other.
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Figure 3.7. 24-OHase transcript fold change following treatment with vitamin D3. HaCaT cells
were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48
hours (c,d). Real-time PCR was performed using primers specific for 24-hydroxylase. Changes in
expression of this gene are presented as fold change relative to controls. A p-value of less than
0.05 is considered significant. Bars with different symbols are significantly different from each
other.
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Figure 3.8. VDR transcript fold change following treatment with vitamin D3. HaCaT cells were
treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 hours
(c,d). Real-time PCR was performed using primers specific for the vitamin D receptor. Changes
in expression of this gene are presented as fold change relative to controls. A p-value of less than
0.05 is considered significant. Bars with different symbols are significantly different from each
other.
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Figure 3.9. REDD1 transcript fold change following treatment with vitamin D3. HaCaT cells were
treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 hours
(c,d). Real-time PCR was performed using primers specific for REDD1. Changes in expression of
this gene are presented as fold change relative to controls. A p-value of less than 0.05 is
considered significant. Bars with different symbols are significantly different from each other.
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Figure 3.10. Gli1 transcript fold change following treatment with vitamin D3. HaCaT cells were
treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 hours
(c,d). Real-time PCR was performed using primers specific for Gli1. Changes in expression of this
gene are presented as fold change relative to controls. A p-value of less than 0.05 is considered
significant. Bars with different symbols are significantly different from each other.
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Figure 3.11. Ras transcript fold change following treatment with vitamin D3. HaCaT cells were
treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 hours
(c,d). Real-time PCR was performed using primers specific for Ras. Changes in expression of this
gene are presented as fold change relative to controls. A p-value of less than 0.05 is considered
significant. Bars with different symbols are significantly different from each other.
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Figure 3.12. Change in phosphorylation of mTOR following treatment with vitamin D3. HaCaT
cells were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours or 48
hours. Whole cell extract (50µg per sample) was compared by western blot analysis. Blots were
probed with antibody specific for phosphorylated mTOR (Ser 2448) and total mTOR. Changes in
phosphorylation of this gene are presented as fold change relative to controls. A p-value of less
than 0.05 is considered significant. Bars with different symbols are significantly different from
each other.
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Figure 3.13. Change in phosphorylation of P70-S6K following treatment with vitamin D3. HaCaT
cells were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours or 48
hours. Whole cell extract (50µg per sample) was compared by western blot analysis. Blots were
probed with antibody specific for phosphorylated P70-S6K (Thr 389) and total P70-S6K. Changes
in phosphorylation of this gene are presented as fold change relative to controls. A p-value of
less than 0.05 is considered significant. Bars with different symbols are significantly different
from each other.
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Figure 3.14. Change in phosphorylation of 4EBP following treatment with vitamin D3. HaCaT
cells were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours or 48
hours. Whole cell extract (50µg per sample) was compared by western blot analysis. Blots were
probed with antibody specific for phosphorylated 4EBP (Thr 37/46) and total 4EBP. Changes in
phosphorylation of this gene are presented as fold change relative to controls. A p-value of less
than 0.05 is considered significant. Bars with different symbols are significantly different from
each other.
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Figure 3.15. Change in phosphorylation of mTOR, P70-S6K, and 4EBP following treatment with
AICAR. HaCaT cells were treated with 1 mM AICAR or vehichle for 48 hours. Whole cell extract
(50µg per sample) was compared by western blot analysis. Blots were probed with antibody
specific for phosphorylated mTOR (Ser 2448) and total mTOR (a), phosphorylated P70-S6K (Thr
389) and total P70-S6K (b), and phosphorylated 4EBP (Thr 37/46) and total 4EBP (c). Changes in
phosphorylation of this gene are presented as fold change relative to controls. A p-value of less
than 0.05 is considered significant. Bars with different symbols are significantly different from
each other.
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CHAPTER 4: Discussion
The vast majority of research indicates that vitamin D3 has anti-proliferative effects in
vitro. These effects have even been shown in clinical studies of breast and colon cancer, and the
results of vitamin D3 treatment are generally positive for these cancers. Unfortunately, data is
lacking and inconclusive in the treatment of basal cell carcinoma. Perhaps one reason for the
varied response to treatment for different tissues is the difference in exposure to UV light
combined with the availability of vitamin D3 metabolizing enzymes. The skin is unique because it
has all of these, and thus it has the potential to synthesize active vitamin D3 de novo, as well as
inactivate it when high levels are no longer desirable. Because of this, it is necessary to perform
cell culture experiments in skin cell models of basal cell carcinoma, and not cells from other
tissues. Unfortunately, experiments are difficult because BCC cells do not proliferate well in
culture. The HaCaT keratinocyte cell line, therefore, is a useful model for skin tissue because it is
immortalized and grows rapidly in culture.
In the present study, HaCaT cells were treated with various concentrations of calcitriol or
cholecalciferol for 24 or 48 hours. As a positive control, cells were also treated with AICAR for 24
or 48 hours, which significantly decreased proliferation relative to controls. The AICAR results
indicate that proliferation of these cells is capable of being inhibited despite high levels of growth
factors in the media. Interestingly, not only did treatments with both calcitriol and cholecalciferol
fail to inhibit proliferation, they actually increased it. Early research involving these cells
indicated that high calcium concentrations may actually render calcitriol treatment proliferative,
however current research rarely considers this.33,34 Calcium concentration in the skin is stratified
and corresponds to the level of differentiation of the cells, with low levels in the stratum basale,
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and high levels in the stratum granulosum.35 If high calcium correlates with a more differentiated
phenotype, it seems counter-intuitive that high levels would also render calcitriol treatment
proliferative, as differentiation is usually associated with growth cessation. Analysis of the
DMEM used in our experiments showed that our cell culture media contained 1.8 mM calcium,
which corresponded to the high concentrations tested in these early experiments. It should be
noted that this is a common formulation used in many cell culture experiments, including those
relevant to the current study. Other early studies suggest that low, physiological concentrations
of calcitriol promoted growth, however, the concentrations tested in the present study were
higher than these and were expected to be inhibitory.36 Taking these older studies into
consideration may make it feasible that vitamin D3 treatment may not inhibit growth under all
conditions. Based on these results, we decided to investigate key effectors in the mTOR and
Hedgehog pathways to understand how their status may impact proliferation in our treatment
groups.
Real time PCR was performed on cDNA from cells that were treated with calcitriol,
cholecalciferol, and ethanol vehicle. Calcitriol treatment had no effect on expression of the
metabolizing 25-hydroxylase and 1α-hydroxylase genes, as it is an end product of their sequential
reactions. Cholecalciferol appeared to increase 25-hydroxylase mRNA following 24 hours of
treatment (p = 0.1), and then significantly decrease it after 48 hours. A significant increase in 1αhydroxylase was seen after 48 hours. Taken together, the expression of these enzymes may
correlate with sequential hydroxylation of cholecalciferol to form calcitriol.
Both calcitriol and cholecalciferol treatment significantly increased 24-hydroxylase (the
vitamin D3 inactivating enzyme) mRNA after 48 hours of treatment.

The 24-hydroxylase
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promoter contains two vitamin D response elements (VDREs) that bind the vitamin D receptor.37
The increase seen here verifies that both calcitriol and cholecalciferol successfully entered the
cells and were capable of exerting an effect on gene expression via the vitamin D receptor (VDR).
Additionally, this verifies that cholecalciferol was successfully hydroxylated by 25-hydroxylase
and 1α-hydroxylase, as only calcitriol binds VDR.38 The thousand-fold increase in expression of
this gene is too substantial to be ignored. 24-hydroxylase is often considered an oncogene
because it results in the degradation of vitamin D3.39 Indeed, inhibition of 24-hydroxylase
enhanced the anti-proliferative properties of calcitriol in prostate cancer cells.40 Perhaps the
major up-regulation of this gene is also somehow responsible for the increase in proliferation
seen here. Another point to consider is that any effects seen in this study may be an artifact of
the limitations of cell culture. 24-hydroxylase inactivation of calcitriol and cholecalciferol in vivo
results in their clearance from the body, while in vivo these products accumulate in the media.
While both forms of vitamin D3 were able to regulate 24-hydroxylase gene expression,
only cholecalciferol had an effect on the VDR transcript. Levels increased significantly with 24
hours of treatment, and then returned to control levels after 48 hours (as protein concentration
was most likely sufficient). However, it cannot be directly inferred that the difference in
expression of VDR mRNA between calcitriol and cholecalciferol treatment groups affected the
activity of VDR protein. REDD1 (a target of VDR transcription regulation) mRNA was significantly
increased by cholecalciferol treatment after 48 hours. However, the trend is also evident for
calcitriol treatment (p = 0.08), so it is most likely that REDD1 mRNA is also increased in this group.
Perhaps cholecalciferol treatment increased VDR expression, which allowed for a faster
accumulation of REDD1, however, this conclusion needs further investigation.
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The most common mutations found in BCC are those affecting the Hedgehog pathway.
Vitamin D3 is perhaps so compelling in the treatment of BCC because multiple studies suggest
that calcitriol and/or cholecalciferol can inhibit activation of this pathway. While some suggest
that the inhibition comes at the level of blocking Smo, independent of the VDR, others say that
calcitriol, via VDR, controls the expression of several of the genes involved. Ultimately, all
suggested means of inhibition result in a decrease in Gli1 mRNA. Analysis of Real Time PCR data
showed that neither calcitriol nor cholecalciferol treatment had any effect on the expression of
Gli1 transcript in the current study. One possible explanation for this is that both forms of vitamin
D3 are incapable of inhibiting this pathway due to the cell culturing conditions. It could be that
the presence of growth factors override the ability of VDR to control the expression of genes in
the pathway. It is possible that another nutrient in the media is blocking the ability of calcitriol
and/or cholecalciferol to bind to and inhibit Smo. A second explanation may be that Gli1 mRNA
can only be reduced when it is over-expressed in the first place. No studies suggest any mutations
in this pathway in HaCaT cells, so it can be assumed that this pathway is not over-active. Testing
this theory might involve the introduction of a deregulating mutation to Ptch or Smo, and then
observation of the effects of vitamin D3 treatment on Gli1 mRNA expression. Regardless of the
cause, the absence of an effect on Gli1 transcript expression in the present study provides two
important pieces of information. First, it supports our findings that vitamin D3 treatment does
not always inhibit proliferation of HaCaT cells. Second, it shows that vitamin D3 treatment does
not upregulate this pathway, and therefore it is not the cause of the increase in proliferation seen
in our WST-1 assay.
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We also looked at the expression of Ras in response to calcitriol and cholecalciferol.
Earlier research in our laboratory showed that Ras was up-regulated in cancer tissue, along with
up-regulation of 1α-hydroxylase. We wanted to confirm that the increase in Ras transcript was
due to a malfunction of the cancer cells, and not somehow caused by increasing concentrations
of calcitriol. Real Time PCR data showed that calcitriol and cholecalciferol treatments had no
effect of Ras expression.
Taken together, the results from Real Time PCR indicate that cholecalciferol is converted
to calcitriol by 25-hydroxylase and 1α-hydroxylase. Calcitriol is then able to bind to VDR, resulting
in up-regulation of REDD1 and 24-hydroxylase. REDD1 inhibits the mTOR pathway, so the
increase in REDD1 we see should lead to inhibition of proliferation. Neither calcitriol nor
cholecalciferol inhibited the Hedgehog pathway, as determined by the lack of effect on Gli1
expression. While this may be partially responsible for the lack of inhibition on cell proliferation,
it does not explain the increase in proliferation seen. To further probe the cause of the
dysfunction, we decided to investigate what is occurring downstream of REDD1. To do so
required the utilization of western blotting, as the signaling involves the phosphorylation status
of key proteins, including mTOR, P70-S6K, and 4EBP.
HaCaT cells were treated with calcitriol, cholecalciferol, or ethanol vehicle for 24 or 48
hours. As a control, cells were also treated with AICAR or DMSO vehicle for 48 hours. The
increase in REDD1 was expected to result in a decrease in phosphorylation of mTOR, which would
inhibit proliferation. After 24 hours of treatment with both calcitriol and cholecalciferol we see
a significant increase in phosphorylation of mTOR (Figure 3.12).

After 48 hours the

phosphorylation of mTOR returns to control levels. Phosphorylation of mTOR results in its
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activation, which leads to downstream signaling that encourages cellular proliferation. This helps
explain the increase in proliferation seen in the WST-1 assay.
To probe whether the activation of mTOR had effects downstream, we also looked at the
phosphorylation of its targets, P70-S6K and 4EBP. Neither treatment had a significant effect on
P70-S6K phosphorylation, however an increasing trend is seen at 24 hours (p < 0.2). The
treatment groups return to levels of controls after 48 hours (Figure 3.13). Next we looked at
4EBP. Neither treatment had an effect on phosphorylation of this protein after 24 hours.
However, after 48 hours of treatment both calcitriol and cholecalciferol had a significant increase
in 4EBP phosphorylation. This clearly helps to explain the increase in cellular proliferation we see
in response to treatment with both forms of vitamin D3. Phosphorylation of 4EBP results in its
inactivation, and removes its inhibition of the translation initiation factor, 4E. This results in the
recruitment of the translation machinery and assembly of the ribosome. Therefore, 4EBP is
essential in controlling the rate of translation in the cell, and its inactivation removes inhibition
of protein synthesis. This, in turn, can contribute to an increase in cellular proliferation.
As mentioned, we also treated cells with AICAR as a positive control.

AICAR

phosphorylates AMPK, which is a sensor of cellular energy status. An increase in p-AMPK signals
a decrease in ATP/ADP ratio, and results in inhibition of proliferation. One way this happens is
by direct control of mTOR activation. Protein analysis via western blot yielded a significant
decrease in phosphorylation of mTOR, P70-S6K, and 4EBP following 48 hours of AICAR treatment
(Figure 3.15). This is essential to explain the decrease in proliferation due to AICAR, but not
Vitamin D3, treatment seen in the WST-1 assay.

When the mTOR pathway is inhibited
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proliferation can also be inhibited. However, more research is needed in order to prove causality,
because AICAR may control other pathways as well.
Under conditions in our laboratory, vitamin D3 treatment increased the proliferation of
HaCaT cells. AICAR treatment showed that cell proliferation was capable of being inhibited in
the media formulation used. Neither form of Vitamin D3 decreased Gli1 transcript levels,
indicating that they do not inhibit the Hedgehog pathway in these conditions. This helped us
understand why proliferation was not inhibited, but to explain why it was increased required
analysis of the mTOR pathway. AICAR treatment also showed that the mTOR pathway was intact,
and inhibition of this pathway may inhibit proliferation. Real-time PCR data showed that REDD1
transcript was increased by cholecalciferol, and most likely by calcitriol as well (p = 0.08). An
increase in REDD1 should result in a decrease in mTOR phosphorylation, but we saw the opposite
effect. Therefore, the dysfunction seen in the inhibition of proliferation by Vitamin D3 must be
presenting at the level of the inhibition of mTOR by REDD1.

Somehow calcitriol and

cholecalciferol treatment either block the negative regulation of REDD1 on mTOR, or they impact
another pathway that activates mTOR, and this activity overwhelms the negative regulation
coming from REDD1. Either way, the negative regulation of vitamin D3 on cellular proliferation is
reversed due to insensitivity of mTOR to REDD1, and activation of the mTOR pathway.
The results presented here suggest that vitamin D3 treatment increases proliferation of
HaCaT cells under conditions in our laboratory. This goes against most current research, which
generally supports the anti-proliferative activity of vitamin D3. Early research from the 1990’s
suggested that high calcium concentrations may render calcitriol proliferative in these cells. Our
media contains 1.8 mM calcium, which corresponds to these high concentrations. Therefore, the
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dysregulation seen in the current study may be occurring due to an interaction between vitamin
D3 and extracellular calcium. However, several current studies culture cells in media containing
1.8 mM calcium, yet still show that vitamin D3 has anti-proliferative properties.12,25
It should be noted that this research does not condemn the use of vitamin D3 in cancer
treatment or nutritional supplementation. The effects vitamin D3 has on bone remodeling,
immune function, and cell proliferation are vast and varied. Normal, physiological concentrations
of vitamin D3 are essential for proper functioning of cells, tissues, organs, and organ systems. The
ability to increase concentrations of vitamin D3 are also essential to protect against stress from
the environment, such as UV rays. However, this research shows that over-supplementation is
not always beneficial. Under HaCaT cell culture conditions in our laboratory, too much of a good
thing turned out to be bad.

Future Directions
In order to determine whether these results are affected by the formulation of the media,
more experiments are required. The next logical experiments would include serum deprivation
to control for the effects of growth factors in the media. Also desirable are experiments
performed in the presence of lower concentrations of calcium.
One interesting question that arose from this project is why treatment had no effect on
control of the Hedgehog pathway. I hypothesize that vitamin D3 only inhibits Gli1 expression
when it is over-expressed.

Testing this would involve either mutating PTCH or Smo, or

transgenically over-expressing Gli1. Doing so would help explain why our data disagree with what
so many other studies suggest.
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The main concern of the current study is that vitamin D3 treatment increased proliferation
of these cells, when we expected to see a decrease. I hypothesize that this is caused by the
extreme increase in 24-hydroxylase gene expression. The skin is unique in its ability to synthesize
and activate vitamin D3, because it is directly exposed to the UV light and it possesses all of the
enzymes required for its conversion to calcitriol. This can lead to a rapid accumulation of
calcitriol, which other organs do not experience. Other organs gradually obtain calcitriol from
the blood, after it has been activated in the liver and kidneys. For this reason, the skin also needs
to be able to inactivate calcitriol rapidly. Treating skin cells with pharmacologic doses of vitamin
D3 resulted in a several thousand-fold increase in 24-hydroxylase. I propose that in addition to
inhibition of calcitriol, 24-hydroxylase has other oncogenic effects. I hypothesize that 24hydroxylase or its product, 1α,24,25(OH)3 D3, is involved in one or more signal transduction
pathways that lead to increased proliferation. Testing this would first involve silencing 24hydroxylase and looking for proliferation inhibition following vitamin D3 treatment. Determining
its direct effect would involve the analysis of the status of several signaling pathways, including
the RAS/RAF/MEK/ERK and PI3K/AKT pathways.
The present study needs to be repeated in primary cells to confirm that our results are
true under even more accurate physiological conditions. While HaCaT cells are a good model for
the skin, they are not the best. Unfortunately, however strong an in vitro model may be, the
results obtained may never truly replicate the influence of organ systems in vivo. Due to the
limitations of cell culture, the only true way to test our results is to sample human tissue.

45

REFERENCES
1. “Skin Cancer: Basal and Squamous Cell.” Cancer.Org. The American Cancer Society, 20 Feb
2014. Web. 24 Feb 2015.
2. American Cancer Society. Cancer Facts and Figures 2014. Atlanta: American Chemical
Society; 2014.
3. Guy GP Jr., Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and Costs of Skin Cancer
Treatment in the U.S., 2002-2006, and 2007-2011. Am J Prev Med 2015; 48(2):183-187.
4. Nitzki F, Becker M, Frommhold A, Schulz-Schaeffer W, Hahn H. Patched knockout mouse
models of basal cell carcinoma. Journal of Skin Cancer 2012; vol. 2012; Article ID 907543,
11 pages.
5. Bikle DD. Vitamin D and cancer: the promise not yet fulfilled. Endocrine 2014; 46:29-38.
6. Bikle DD, Elalieh, H, Welsh J, Oh D, Cleaver J, Teichert A. Protective role of vitamin D
signaling in skin cancer formation. J Steroid Biochem 2013; 136:271-279.
7. Ellison TI, Smith MK, Gilliam, AC, MacDonald PN. Inactivation of the vitamin D receptor
enhances susceptibility of murine skin to UV-induced tumorigenesis. J Invest Dermatol
2008 October; 128(10):2508-2517.
8. Teichert AE, Elalieh H, Elias PM, Welsh J, Bikle D. Overexpression of hedgehog signaling is
associated with epidermal tumor formation in vitamin D receptor-null mice. J Invest
Dermatol 2011; 131:2289-2297.
9. Deeb KK, Trump DL, Johnson, CS. Vitamin D Signaling pathways in cancer: potential for
anticancer therapeutics. Nat Rev Cancer 2007; 7:684-700.

46

10. Hunter DJ, Colditz GA, Stampfer MJ, Rosner B, Willett WC, Speizer FE. Diet and risk of basal
cell carcinoma of the skin in a prospective cohort of women. Ann Epidemiol 1992;
2(3):231-239.
11. van Dam RM, Huang Z, Giovannucci E, Rimm EB, Hunter DJ, Colditz GA, Stampfer MJ,
Willett WC. Diet and basal cell carcinoma of the skin in a prospective cohort of men. Am
J Clin Nutr 2000; 71(1):135-141.
12. Tang JY, Parimi N, Wu A, Boscardin WJ, Shikany JM, Chren MM, Cummings SR, Epstein EH
Jr., Bauer DC. Inverse association between serum 25(OH) vitamin D levels and nonmelanoma skin cancer in elderly men. Cancer Cause Control 2010; 21:387-391.
13. Asgari MM, Tang J, Warton EM, Chren MM, Quesenberry CP Jr., Bikle D, Horst RL,
Orentreich N, Vogelman JH, Friedman GD. Association of prediagnostic serum vitamin D
levels with the development of basal cell carcinoma. J Invest Dermatol 2010;
130(5):1438-1443.
14. Eide MJ, Johnson DA, Jacobsen GR, Krajenta RJ, Rao DS, Lim HW, Johnson CC. Vitamin D
and nonmelanoma skin cancer in a health maintenance organization cohort. Arch.
Dermatol 2011; 147(12):1379-1384.
15. Vitamin D. (n.d.) in Encyclopedia Brittanica online. Retrieved from
http://www.britannica.com/EBchecked/topic/631106/vitamin-D.
16. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: Metabolism. Endocrin
Metab Clin 2010; 39(2):243-253.
17. Nemazannikova N, Antonas K, Dass CR. Vitamin D: Metabolism, molecular mechanisms,
and mutations to malignancies. Mol Carcinogen 2014; 53:421-431.

47

18. Schuessler M, Astecker N, Herzig G, Vorisek G, Schuster I. Skin is an autonomous organ in
synthesis, two-step activation and degradation of vitamin D3: CYP27 in epidermis
completes the set of essential vitamin D3-hydroxylases. Steroids 2001; 66:399-408.
19. Lisse TS. and Hewison M. Vitamin D: A new player in the world of mTOR signaling. Cell
Cycle 2011; 10(12):1888-1889.
20. Lisse TS, Liu T, Irmler M, Beckers J, Chen H, Adams JS, Hewison M. Gene targeting by the
vitamin D response element binding protein reveals a role for vitamin D in osteoblast
mTOR signaling. FASEB J 2011; 25:937-947.
21. Castellano E and Downward J. RAS interaction with PI3K: More than just another effector
pathway. Genes Cancer 2011; 2(3):261-274.
22. Wei L and Xu Z. Cross-signaling among phosphinositide-2 kinase, mitogen-activated protein
kinase and sonic hedgehog pathways exists in esophageal cancer. Int J Cancer 2011;
129:275-284.
23. Khasawneh R. Desensitization of basal cell carcinoma to the anti-tumoral effect of vitamin
D. Diss. Wayne State University. 2013.
24. Rozenchan PB, Folgueira MAAK, Katayama MLH, Snitcovsky IML, Brentani MM. Ras
activation is associated with vitamin D receptor mRNA instability in HC11 mammary
cells. J Steroid Biochem 2004; 92:89-95.
25. Uhmann A, Niemann H, Lammering B, Henkel C, Heb I, Nitzki F, Fritsch A, Prüfer N,
Rosenberger A, Dullin C, Schraepler A, Reifenberger J, Schweyeer S, Pietsch T, Strutz F,
Schulz-Schaeffer W, Hahn H. Antitumoral effects of calcitriol in basal cell carcinomas

48

involve inhibition of hedgehog signaling and induction of vitamin D receptor signaling
differentiation. Mol Cancer Ther 2011; 10:2179-2188.
26. Tang JY, Xiao TZ, Oda Y, Chang KS, Shpall E, Wu A, So P, Hebert J, Bikle D, Epstein Jr EH.
Vitamin D3 inhibits hedgehog signaling and proliferation in murine basal cell
carcinomas. Cancer Prev Res 2011; 4:744-751.
27. Wang Y, Ding Q, Yen C, Xia W, Izzo JG, Lang J, Li C, Hsu J, Miller SA, Wang X, Lee D, Hsu J,
Huo L, LaBaff AM, Liu D, Huang T, Lai C, Tsai F, Chang W, Chen C, Wu T, Buttar NS, Wang
K, Wu Y, Wang H, Ajani J. The crosstalk of mTOR/S6K1 and hedgehog pathways. Cancer
Cell 2012; 21:374-387.
28. Mazumdar T, DeVecchio J, Agyeman A, Shi T, Houghton JA. The GLI genes as the molecular
switch in disrupting hedgehog signaling in colon cancer. Oncotarget 2011; 2:638-645.
29. Mills LD, Zhang Y, Marler RJ, Herreros-Villanueva M, Zhang L, Almada LL, Couch F, Wetmore
C, Pasca di Magliano M, Fernandez-Zapico ME. Loss of the transcription factor GLI1
identifies a signaling network in the tumor microenvironment mediating KRAS
oncogene-induced transformation. J Biol Chem 2013; 288:11786-11794.
30. Philpott MP, Bergamaschi D, Storey A. Models for Skin Cancer. The Cancer Handbook.
2007.
31. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal
keratinization in a spontaneously immortalized aneuploidy human keratinocyte cell line.
J Cell Biol 1988; 106:761-771.
32. Saha AK, Persons K, Safer JD, Luo Z, Holick MF, Ruderman NB. AMPK regulation of the
growth of cultured human keratinocytes. Biochem Bioph Res Co 2006; 349:519-524.

49

33. Gniakecki R. Stimulation versus inhibition of keratinocyte growth by 1,25-dihydroxyvitamin
D3 : dependence on cell culture conditions. J Invest Dermatol 1996; 106:510-516.
34. Garach-Jehoshua O, Ravid A, Liberman U, Koren R. 1,25-Dihydroxyvitamin D3 increases the
growth-promoting activity of autocrine epidermal growth factor receptor ligands in
keratinocytes. Endocrinology 1999; 140(2):713-721.
35. Bikle DD, Ng D, Tu C-L, Oda Y, Xie Z. Calcium- and vitamin D-regulated keratinocyte
differentiation. Mol Cell Endocrinol 2001; 177:161-171.
36. Bollag WB, Ducote J, Harmon CS. Biphasic effect of 1,25-dihydroxyvitamin D3 on primary
mouse epidermal keratinocyte proliferation. J Cell Physiol 1995; 163:248-256.
37. Chen K-S, DeLuca HF. Cloning of the human 1 α, 25-dihydroxyvitamin D-3 24-hydroxylase
gene promoter and identification of two vitamin D-response elements. Biochim Biophys
ACTA 1995; 1263:1-9.
38. Kato S. The function of the vitamin D receptor in vitamin D action. J Biochem 2000;
127:717-722.
39. Luo W, Hershberger PA, Trump DL, Johnson CS. 24-hydroxylase in cancer: Impact of vitamin
D-based anticancer therapeutics. J Steroid Biochem 2013; 136:252-257.
40. Ly LH, Zhao X-Y, Holloway L, Feldman D. Liarozole acts synergistically with 1α, 25dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by
blocking 24-hydroxylase activity. Endocrinology 1999; 140(5):2071-2076.

50

ABSTRACT
DESENSITIZATION OF HACAT KERATINOCYTES TO VITAMIN D3 OCCURS VIA LOSS OF REDD1
REGULATION OF THE MTOR PATHWAY
by
MICHELLE LEIGH JONES
May 2015
Advisor: Dr. Ahmad R. Heydari
Major: Nutrition and Food Science
Degree: Master of Science

Vitamin D3 treatment has long been considered in the treatment of cancer due to its welldocumented anti-proliferative effects in vitro. While clinical studies have been positive in other
cancers, results are inconclusive in cases of basal cell carcinoma. To better understand the
reasons underlying this disconnect, this study employs an immortalized human keratinocyte cell
line (HaCaT) to observe the effects of vitamin D3 treatment on cellular proliferation. The results
show that both activate vitamin D3 (calcitriol) and its precursor (cholecalciferol) increase
proliferation of these cells. Real-time PCR and western blot data indicate that the mTOR pathway
becomes activated despite increased VDR signaling and expression of REDD1. Treatment was
also unable to inhibit the Hedgehog signaling pathway.
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